|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 656.01 USD | +0.63% |
|
-3.06% | -15.01% |
| 07-24 | US FDA approves Outlook Therapeutics' eye disease drug | RE |
| 07-24 | Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO | DJ |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 66,742 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | -15.72% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 58,919 | 56,229 | 52,975 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | -19.61% | -4.57% | -5.79% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 17.3x | 13.8x | 12x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 1.96x | 1.71x | 1.51x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | -1.96x | 0.5x | 0.8x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 4.2x | 3.79x | 3.52x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 3.71x | 3.19x | 2.79x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 9.57x | 8.27x | 6.96x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 11.1x | 8.66x | 7.13x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 9.53x | 9.23x | 7.73x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 10.5% | 10.8% | 12.9% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.874 | 4.421 | 4.986 |
| Rate of return | - | - | - | - | 0.46% | 0.59% | 0.67% | 0.76% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 37.82 | 47.4 | 54.77 |
| Distribution rate | - | - | - | - | 8.49% | 10.2% | 9.33% | 9.1% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 15,873 | 17,608 | 18,959 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 6,156 | 6,803 | 7,614 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 5,309 | 6,496 | 7,431 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 3,976 | 5,025 | 5,677 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -7,823 | -10,513 | -13,767 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 656.01 | 656.01 | 656.01 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 101,739 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/2/24 | 2/4/25 | 1/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.35x | 3.71x | 9.57x | 0.59% | 66.74B | |
| 26.36x | 5.45x | 16.03x | 0.6% | 53.32B | |
| 37.26x | 12.6x | 24.05x | -.--% | 48.12B | |
| -42.39x | 3.06x | 9.03x | 3.57% | 38.25B | |
| 25.06x | 3.49x | 11.87x | -.--% | 29.85B | |
| 56.96x | 3.39x | 25.31x | -.--% | 23.51B | |
| -6.24x | 8.61x | -5.3x | -.--% | 21.45B | |
| 64.96x | 6.38x | 43.91x | -.--% | 19.97B | |
| -37.77x | 18x | -49.29x | -.--% | 16.47B | |
| 24.05x | 5.15x | 13.48x | -.--% | 16.38B | |
| Average | 16.56x | 6.99x | 9.87x | 0.48% | 33.41B | |
| Weighted average by Cap. | 17.23x | 6.40x | 12.33x | 0.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
